Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | NMT2 | O60551 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.32 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 4/20 | 0.31 |
| ▸ | Q9HBH1 | 1/20 | 0.30 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812439 | 0.98 | SLC15A2 (0.44) | SLC15A2MMP1NMT2NMT1OPRK1 | |
| SCHEMBL5598844 | 0.90 | SLC15A2 (0.52) | SLC15A2OPRK1CALCRL | |
| SCHEMBL4587124 | 0.90 | SLC15A2 (0.54) | SLC15A2MMP1NMT2NMT1CALCRL | |
| SCHEMBL4589980 | 0.90 | SLC15A2 (0.54) | SLC15A2MMP1NMT2NMT1CALCRL | |
| SCHEMBL2815083 | 0.88 | SLC15A2 (0.54) | SLC15A2MMP1NMT2NMT1CALCRL | |
| SCHEMBL2243005 | 0.88 | SLC15A2 (0.54) | SLC15A2MMP1NMT2NMT1CALCRL | |
| SCHEMBL4588260 | 0.87 | SLC15A2 (0.42) | SLC15A2MMP1GHSRPDF | |
| SCHEMBL9616734 | 0.86 | SLC15A2 (0.52) | SLC15A2MMP1NMT2NMT1CALCRL | |
| SCHEMBL4587382 | 0.85 | SLC15A2 (0.41) | SLC15A2MMP1OPRK1GHSR | |
| SCHEMBL4588264 | 0.85 | SLC15A2 (0.41) | SLC15A2MMP1OPRK1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | PROCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | RBP1, RBP4, SOD1 | SLC15A2 2656/4885MMP1 625/4885NMT2 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.